Roche-HIV.com
 
  Home | Disclaimer | Sitemap | Glossary | Library cart | Useful links | Keep me informed | Roche worldwide | Contact webmaster  
  
   Search this site
  Roche in HIV
  Understanding HIV
 
  About HIV
 
  Management issues
 
  Resistance
  Adherence
 
  Guidelines (HIV and HCV)
  Pharmaceutical products  
  Commitment to research  
  Commitment to access  
  Conferences  
  News and features
  Healthcare professionals

A Guide to Protease Inhibitor (PI) Boosting

Disclaimer: This section contains information on experimental dosages of saquinavir and ritonavir. Please refer to complete prescribing information.

CONTENTS OF THIS SECTION

Introduction

How are pharmacokinetics measured

How is antiviral efficacy measured

The concept of PI boosting

  • How is PI boosting achieved?
  • How does ritonavir increase exposure to the PIs?
  • What is the effect of PI boosting?
  • Is simultaneous dosing of ritonavir and PI required for optimal boosting?
  • What dose of ritonavir is required for optimum boosting?

Safety considerations for PI boosting

  • Use of ritonavir as part of a PI boosting regimen
  • Increased exposure to the PI when boosted
  • The impact of additional ritonavir on PI drug interactions

Double boosting strategies

Summary: key considerations when evaluating the use of ritonavir in a boosted regimen

Next »
Home | Disclaimer | Sitemap | Glossary | Library cart | Useful links | Keep me informed | Roche worldwide
All information contained in this website is generated and maintained by F. Hoffmann-La Roche, Ltd, Basel, Switzerland. This site is intended for use by physicians only. This site is not intended for residents of the United States of America.
Copyright 2006 F. Hoffmann La Roche Ltd.
Contact webmaster